BIOMARIN PHARMACEUTICAL INC Share-based Payment Arrangement, Amount Capitalized
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Share-based Payment Arrangement, Amount Capitalized of $27.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, amount capitalized for the quarter ending 2022-03-31 was $5.20M, a 18.18% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, amount capitalized for the quarter ending 2021-03-31 was $4.40M, a 4.35% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, amount capitalized for the quarter ending 2020-12-31 was $5.20M, a 26.76% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, amount capitalized for the quarter ending 2020-09-30 was $4.90M, a 3.92% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, amount capitalized for fiscal 2025 was $27.20M, a 3.89% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, amount capitalized for fiscal 2024 was $28.30M, a 30.41% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, amount capitalized for fiscal 2023 was $21.70M, a 1.88% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, amount capitalized for fiscal 2022 was $21.30M, a 6.50% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2025-12-31 | $27.20M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $28.30M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $21.70M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $21.30M 10-K · filed 2025-02-24 | |||
| 2022-03-31 | $5.20M 10-Q · filed 2022-04-29 | |||
| 2021-12-31 | $20.00M 10-K · filed 2024-02-26 | |||
| 2021-03-31 | $4.40M 10-Q · filed 2022-04-29 | $9.60M derived: sum of 2 quarters · filed 2023-02-27 | $14.50M derived: sum of 3 quarters · filed 2023-02-27 | $20.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $10.10M derived: sum of 2 quarters · filed 2023-02-27 | $15.60M derived: sum of 3 quarters · filed 2023-02-27 | $20.10M 10-K · filed 2023-02-27 |
| 2020-09-30 | $4.90M 10-Q · filed 2020-11-06 | $10.40M derived: sum of 2 quarters · filed 2020-11-06 | $14.90M 10-Q · filed 2020-11-06 | $22.10M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $5.50M 10-Q · filed 2020-08-05 | $10.00M 10-Q · filed 2020-08-05 | $17.20M derived: sum of 3 quarters · filed 2022-02-25 | $22.30M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $4.60M 10-Q · filed 2021-04-30 | $11.70M derived: sum of 2 quarters · filed 2022-02-25 | $16.80M derived: sum of 3 quarters · filed 2022-02-25 | $21.10M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $7.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $12.20M derived: sum of 2 quarters · filed 2022-02-25 | $16.50M derived: sum of 3 quarters · filed 2022-02-25 | $20.30M 10-K · filed 2022-02-25 |
| 2019-09-30 | $5.10M 10-Q · filed 2020-11-06 | $9.40M derived: sum of 2 quarters · filed 2020-11-06 | $13.20M 10-Q · filed 2020-11-06 | $18.90M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $4.30M 10-Q · filed 2020-08-05 | $8.10M 10-Q · filed 2020-08-05 | $13.80M derived: sum of 3 quarters · filed 2021-02-26 | $19.10M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $3.80M 10-Q · filed 2020-05-01 | $9.50M derived: sum of 2 quarters · filed 2021-02-26 | $14.80M derived: sum of 3 quarters · filed 2021-02-26 | $20.20M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $5.70M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $11.00M derived: sum of 2 quarters · filed 2021-02-26 | $16.40M derived: sum of 3 quarters · filed 2021-02-26 | $20.00M 10-K · filed 2021-02-26 |
| 2018-09-30 | $5.30M 10-Q/A · filed 2019-11-04 | $10.70M derived: sum of 2 quarters · filed 2019-11-04 | $14.30M 10-Q/A · filed 2019-11-04 | $18.20M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $5.40M 10-Q · filed 2019-08-02 | $9.00M 10-Q · filed 2019-08-02 | $12.90M derived: sum of 3 quarters · filed 2020-02-27 | $17.40M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $3.50M 10-Q · filed 2019-04-29 | $7.50M derived: sum of 2 quarters · filed 2020-02-27 | $12.00M derived: sum of 3 quarters · filed 2020-02-27 | $16.40M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $8.50M derived: sum of 2 quarters · filed 2020-02-27 | $12.90M derived: sum of 3 quarters · filed 2020-02-27 | $16.10M 10-K · filed 2020-02-27 |
| 2017-09-30 | $4.50M 10-Q · filed 2018-10-26 | $8.90M derived: sum of 2 quarters · filed 2018-10-26 | $12.10M 10-Q · filed 2018-10-26 | $14.50M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $4.40M 10-Q · filed 2018-08-03 | $7.60M 10-Q · filed 2018-08-03 | $10.00M derived: sum of 3 quarters · filed 2019-02-28 | $13.50M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $3.20M 10-Q · filed 2018-04-27 | $5.60M derived: sum of 2 quarters · filed 2019-02-28 | $9.10M derived: sum of 3 quarters · filed 2019-02-28 | $12.40M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $5.90M derived: sum of 2 quarters · filed 2019-02-28 | $9.20M derived: sum of 3 quarters · filed 2019-02-28 | $11.40M 10-K · filed 2019-02-28 |
| 2016-09-30 | $3.50M 10-Q · filed 2017-10-31 | $6.80M derived: sum of 2 quarters · filed 2017-10-31 | $9.00M 10-Q · filed 2017-10-31 | $12.10M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $3.30M 10-Q · filed 2017-08-02 | $5.80M 10-Q · filed 2017-08-02 | $8.60M derived: sum of 3 quarters · filed 2018-02-26 | $11.40M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $2.50M 10-Q · filed 2017-05-04 | $5.30M derived: sum of 2 quarters · filed 2018-02-26 | $8.10M derived: sum of 3 quarters · filed 2018-02-26 | $11.10M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $5.60M derived: sum of 2 quarters · filed 2018-02-26 | $8.60M derived: sum of 3 quarters · filed 2018-02-26 | $11.10M 10-K · filed 2018-02-26 |
| 2015-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $5.80M derived: sum of 2 quarters · filed 2016-11-03 | $8.30M 10-Q · filed 2016-11-03 | $10.80M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $3.00M 10-Q · filed 2016-08-08 | $5.50M 10-Q · filed 2016-08-08 | $8.00M derived: sum of 3 quarters · filed 2017-02-27 | $9.80M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $2.50M 10-Q · filed 2016-05-02 | $5.00M derived: sum of 2 quarters · filed 2017-02-27 | $6.80M derived: sum of 3 quarters · filed 2017-02-27 | $8.60M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $4.30M derived: sum of 2 quarters · filed 2017-02-27 | $6.10M derived: sum of 3 quarters · filed 2017-02-27 | $8.20M 10-K · filed 2017-02-27 |
| 2014-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $3.60M derived: sum of 2 quarters · filed 2015-11-02 | $5.70M 10-Q · filed 2015-11-02 | $7.60M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $3.90M 10-Q · filed 2015-08-05 | $5.80M derived: sum of 3 quarters · filed 2016-02-29 | $7.60M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $2.10M 10-Q · filed 2015-05-05 | $4.00M derived: sum of 2 quarters · filed 2016-02-29 | $5.80M derived: sum of 3 quarters · filed 2016-02-29 | $7.20M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $3.70M derived: sum of 2 quarters · filed 2016-02-29 | $5.10M derived: sum of 3 quarters · filed 2016-02-29 | $6.10M 10-K · filed 2016-02-29 |
| 2013-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $3.20M derived: sum of 2 quarters · filed 2014-10-28 | $4.20M 10-Q · filed 2014-10-28 | |
| 2013-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $2.40M 10-Q · filed 2014-07-31 | ||
| 2013-03-31 | $1.00M 10-Q · filed 2014-05-02 | |||
| 2012-12-31 | $4.30M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $5.30M 10-K · filed 2014-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |